Omigapil - Santhera Pharmaceuticals

Drug Profile

Omigapil - Santhera Pharmaceuticals

Alternative Names: CGP 3466; CGP 3466 maleate; CGP 3466B; SNT 317; TCH 346

Latest Information Update: 10 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Novartis
  • Developer Novartis; Santhera Pharmaceuticals
  • Class Antiparkinsonians; Neuroprotectants; Oxepins; Small molecules
  • Mechanism of Action Apoptosis inhibitors; Glyceraldehyde 3 phosphate dehydrogenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Muscular dystrophies
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Muscular dystrophies
  • Discontinued Amyotrophic lateral sclerosis; Motor neuron disease; Parkinson's disease

Most Recent Events

  • 05 Apr 2018 Interim pharmacokinetic and adverse events data from the phase I CALLISTO trial in Muscular-dystrophies released by Santhera Pharmaceuticals
  • 05 Apr 2018 Santhera Pharmaceuticals completes the phase I CALLISTO trial in Muscular-dystrophies in USA (NCT01805024)
  • 06 Feb 2018 Omigapil is still in phase I development for Muscular-dystrophies in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top